Antibiotics and Adverse Events

Authors and Disclosures

Karri A. Bauer^a, Ravina Kullar^a,*, Mark Gilchrist^b and Thomas M. File Jr.<sup>c,d

a</sup>MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA, ^bImperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK, ^cDepartment of Internal Medicine, Northeast Ohio Medical University, Rootstown and ^dDivision of Infectious Diseases, Summa Health, Akron, Ohio, USA
*Current address: Expert Stewardship, Inc.; Newport Beach, California, USA.

Correspondence to
Karri A. Bauer, MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Tel: +1 614 530 9973; e-mail: kbauera@gmail.com

Conflicts of interest
At the time of writing, R. K. was employed by Merck & Co., Inc, MRL, Kenilworth, NJ, USA. R.K. is now employed by Expert Stewardship, Inc.; Newport Beach, CA, USA.

Sidebar

Key Points

• AMR is a global threat worldwide, with deaths associated with AMR infections projected to exceed 10 million per year by the year 2050.

• ASPs can mitigate some of this resistance, with the benefits well recognized; however, if we are to truly advance the state of AMS, the principles and practices should align with patient safety.

• Recent findings have demonstrated the prevalence of antibiotic-associated adverse events.

• Currently, there is a significant gap in ASPs correlating initiatives with patient safety goals, including reductions in antibiotic-associated ADEs and multidrug-resistant infections.

• In this article, we provide the rationale for why ASPs are best suited to lead a collaborative effort to prevent antibiotic-associated ADEs and multidrug-resistant infections.